source
- Mwyngil Therapeutics launches obesity program that avoids GLP-1 pathwayMwyngil Therapeutics, a newly formed biotech startup, is pursuing obesity treatments that do not target the GLP-1 receptor, a pathway that has dominated recent weight-loss drug development. CEO Lu…
- Scientists and stakeholders overwhelmingly oppose White House grantmaking overhaul, analysis findsResearchers at the University of North Carolina at Chapel Hill, working with STAT, examined a flood of public comments on a White House proposal to revamp the federal "Uniform Guidance" that govern…